Jane Street Group LLC Buys New Holdings in Delcath Systems, Inc. (NASDAQ:DCTH)

Jane Street Group LLC purchased a new position in Delcath Systems, Inc. (NASDAQ:DCTH) in the third quarter, Holdings Channel reports. The fund purchased 12,208 shares of the company’s stock, valued at approximately $110,000.

Several other large investors have also recently bought and sold shares of DCTH. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Delcath Systems during the third quarter worth approximately $102,000. Riverwater Partners LLC purchased a new position in shares of Delcath Systems in the 3rd quarter valued at approximately $161,000. Cubist Systematic Strategies LLC acquired a new position in Delcath Systems in the 2nd quarter valued at $370,000. Renaissance Technologies LLC purchased a new position in Delcath Systems during the second quarter worth about $694,000. Finally, State Street Corp lifted its holdings in shares of Delcath Systems by 12.4% in the 3rd quarter. State Street Corp now owns 85,457 shares of the company’s stock valued at $772,000 after buying an additional 9,400 shares during the period. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Trading Down 0.8 %

Shares of NASDAQ DCTH opened at $12.69 on Wednesday. Delcath Systems, Inc. has a 12-month low of $3.70 and a 12-month high of $13.30. The company has a market cap of $405.75 million, a P/E ratio of -9.40 and a beta of 0.87. The stock has a fifty day moving average price of $11.33 and a 200 day moving average price of $9.83.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Delcath Systems in a research report on Tuesday. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.